GSK
27 articole · RSS
GSK Romania Sales Slightly Down In 2012 On Increased Competition For Generics
Sales of GlaxoSmithKline’s Romanian subsidiary declined slightly last year to RON637.4 million from RON643.8 million in 2011, according to Cegedim data, which GSK Romania manager Pascal Prig...
GlaxoSmithKline To Close Its Medicines Factory In Brasov Unless It Finds Buyer
GSK Romania is seeking a buyer for its medicines production line in Brasov, central Romania, which it will otherwise shut down in 2015.
GlaxoSmithKline’s Romanian Plant Reaches EUR100M Turnover
Europharm Brasov, the drug plant of UK giant GlaxoSmithKline, ended last year with turnover of around EUR100 million, up by around 10% on 2010.
GlaxoSmithKline Completes $7M Investment At Brasov Plant
UK medicine maker GlaxoSmithKline (GSK) on Tuesday announced it has completed a $7 million investment in two production lines at the plant it owns in central Romanian city of Brasov..
GSK Romania To Boost Exports To 75% Of Output In 2012
Pharmaceutical company GlaxoSmithKline (GSK), which owns drug maker Europharm in Brasov (central Romania), expects to sell 75% of its output abroad next year, compared with 60% this year and...
GSK: Romanian Market Grows Because Of Stringent Medical Needs
Romania’s pharmaceutical market is a market of contrasts. On the one hand it is extremely unpredictable, which makes it impossible to know whether one will get good or bad news tomorrow, and...
GSK Takes Two Romanian Managers To London
UK pharmaceutical giant GlaxoSmithKline (GSK) promoted two Romanians, Mihaela Ianosev, a medical director, and Roxana Precu, a retail business unit director, to London, where they are set to...
Miron Strikes Deal With GSK Again. This Time As A Buyer
Ropharma (RPH.RO) forecasts a turnover of 400 million lei (EUR96 million) for this year, up 14% from 2010, a figure that will bring its indirect owner, local businessman Mihai Miron, amongst...
GSK Invests EUR5M In Brasov Production Unit
UK drug maker GlaxoSmithKline (GSK) has budgeted investments worth 21 million lei (EUR5 million) in its Brasov plant, with one of the projects being a lab set to be completed in 2012.